Organogenesis Holdings Inc
NASDAQ:ORGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pool Corp
NASDAQ:POOL
|
US |
|
Airgain Inc
NASDAQ:AIRG
|
US |
|
Condor Gold PLC
LSE:CNR
|
UK |
|
Zhejiang Orient Gene Biotech Co Ltd
SSE:688298
|
CN |
|
H
|
Hitachi Zosen Corp
TSE:7004
|
JP |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
302.1m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
66.2B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Organogenesis Holdings Inc
Glance View
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Organogenesis Holdings Inc is 75.6%, which is in line with its 3-year median of 75.6%.
Over the last 3 years, Organogenesis Holdings Inc’s Gross Margin has decreased from 76.7% to 75.6%. During this period, it reached a low of 74.5% on Sep 30, 2025 and a high of 76.9% on Mar 31, 2023.
